1. CT imaging phenotypes linked to CA125 and HE4 biomarkers are highly predictive in discriminating between hereditary and sporadic ovarian cancer patients
   Lucia Manganaro et al, 2022, Tumor Biology CrossRef
2. The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients—results from the OVCAD study
   Mani Nassir et al, 2016, Tumor Biology CrossRef
3. Ovarian cancer recurrence and early detection: may HE4 play a key role in this open challenge? A systematic review of literature
   Stella Capriglione et al, 2017, Medical Oncology CrossRef
4. Identification of high-risk patients by human epididymis protein 4 levels during follow-up of ovarian cancer
   KARINA DAHL STEFFENSEN et al, 2016, Oncology Letters CrossRef
5. Prognostic value of serum HE4 in patients with advanced ovarian, fallopian tube, and peritoneal carcinoma
   Dong Mi et al, 2020, Archives of Gynecology and Obstetrics CrossRef
6. Role of serum HE4 as a prognostic marker in carcinoma of the ovary
   Vijay Kumar et al, 2019, Indian Journal of Cancer CrossRef
7. The Role of CA 125 as Tumor Marker: Biochemical and Clinical Aspects
   Patrizia Bottoni et al, 2015, Advances in Cancer Biomarkers CrossRef
8. Determination of reference intervals of serum levels of human epididymis protein 4 (HE4) in Chinese women
   Yaping Tian et al, 2015, Journal of Ovarian Research CrossRef
9. An overview of the development and application of the sonographic scoring system: differentiation of malignant from benign ovarian tumors
   Z. H. Jiang et al, 2016, Archives of Gynecology and Obstetrics CrossRef
10. Surveillance après traitement initial d’une tumeur épithéliale de l’ovaire, place du traitement hormonal de la ménopause et de la contraception. Article rédigé sur la base de la recommandation nationale de bonnes pratiques cliniques en cancérologie intitulée « Conduites à tenir initiales devant des patientes atteintes d’un cancer épithélial de l’ovaire » élaborée par FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY sous l’égide du CNGOF et labellisée par l’INCa
    C. Sénéchal et al, 2019, Gynécologie Obstétrique Fertilité & Sénologie  CrossRef
11. Evaluation of follow-up observation using human epididymis protein 4, a tumor marker, in patients with ovarian cancer
    Masaya Uno et al, 2023, Obstetrics & Gynecology Science CrossRef
12. The role of novel biomarker HE4 in the diagnosis, prognosis and follow-up of ovarian cancer: a systematic review
    Giuseppe Scaletta et al, 2017, Expert Review of Anticancer Therapy CrossRef
13. HE4 and CA125 serum biomarker monitoring in women with epithelial ovarian cancer
    Alexandra Samborski et al, 2022, Tumor Biology CrossRef
14. The Role of HE4 in Ovarian Cancer Follow-up: A Review
    Elisa Piovano et al, 2014, International Journal of Gynecologic Cancer CrossRef
15. Low 25-OH vitamin D levels at time of diagnosis and recurrence of ovarian cancer
    Teresa Granato et al, 2016, Tumor Biology CrossRef
16. Evaluation of He4 Use in the Diagnosis of Ovarian Cancer: First and Second Recurrence, and an Analysis of HE4 Concentration during Second- and Third-Line Chemotherapy
    Anita Chudecka-Głaz et al, 2023, Diagnostics CrossRef
17. Role of human epididymis protein 4 (HE4) in detecting recurrence in CA125 negative ovarian cancer patients
    Francesco Plotti et al, 2019, International Journal of Gynecologic Cancer CrossRef
18. Serum Human Epididymis Protein 4 as a Prognostic Marker in Cervical Cancer
    Woo Yeon Hwang et al, 2022, Cancer Control CrossRef
19. Is HE4 Superior over CA-125 in the Follow-up of Patients with Epithelial Ovarian Cancer?
    Khalid El Bairi et al, 2020, Current Drug Targets CrossRef
20. Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factors
    J. McGee et al, 2017, Annals of Oncology CrossRef
21. Predictive Value of HE4 in Platinum-Based Chemotherapy for Ovarian Cancer: A Systematic Review
    Yue Han et al, 2021, Frontiers in Oncology CrossRef